CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.

[1]  J. Berek,et al.  Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Whiteside,et al.  Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay , 2003 .

[3]  R. Kreienberg,et al.  Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. , 2003, American journal of obstetrics and gynecology.

[4]  J. Berek,et al.  Biologic and immunologic therapies for ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[6]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[7]  T. Geijtenbeek,et al.  Immune escape through C-type lectins on dendritic cells. , 2002, Trends in immunology.

[8]  K. Shigemasa,et al.  The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure , 2002, Tumor Biology.

[9]  B. Yin,et al.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene , 2002, International journal of cancer.

[10]  R. Ozols.  Recurrent ovarian cancer: evidence-based treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[12]  D. Mann,et al.  Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. , 2001, Clinical immunology.

[13]  T. O'brien,et al.  The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences , 2001, Tumor Biology.

[14]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[15]  R. Baum,et al.  Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. , 2001, Cancer biotherapy & radiopharmaceuticals.

[16]  T. Whiteside,et al.  Generation of PSA‐reactive effector cells after vaccination with a PSA‐based vaccine in patients with prostate cancer , 2000, The Prostate.

[17]  T. Whiteside,et al.  Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. , 2000, Blood.

[18]  P. Ricciardi-Castagnoli,et al.  Fcγ Receptor–mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I–restricted Antigen Presentation after Immune Complex Internalization , 1999, The Journal of experimental medicine.

[19]  R. Baum,et al.  Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) , 1998, Cancer Immunology, Immunotherapy.

[20]  G. Freeman,et al.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Giacomini,et al.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[23]  J. Berek,et al.  Specific keynote: immunological therapy for ovarian cancer. , 2003, Gynecologic oncology.